Halasz acquired the shares for a total consideration of A$15,680, or $0.016 per share.
This has increased her indirect holding to 4.1 million fully paid ordinary shares. Halasz also directly holds over 1 million fully paid ordinary shares.
Cellmid is a company with near term cash flow and a diversified pipeline of products.
The company's over-the-counter évolis® topical hair growth products, which were launched in Australian pharmacies in late June this year, continue to surpass expectations.
Through its controlled entity Advangen International Pty Ltd, Cellmid earlier this year struck agreement with almost 700 Australian pharmacies to stock its scientifically validated évolis® hair growth product range - well above its projected target of 400 stockists by June 2013.
Stockists include some of the largest pharmacy banner groups such as Priceline, Terry White and regional groups like National Pharmacies and their respective online stores.
Cellmid is now aiming to have 25%, or 1,300, Australian pharmacies, as well as 210 salons, stocking its évolis® range by the end of 2013.
The company also has two cancer diagnostics in the pipeline, slated for market release in 2013.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.